IGF::OT::IGF: SBIR PHASE II, TOPIC 326: DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS

在肿瘤中有两种主要的细胞类型：成熟的癌细胞占肿瘤的大部分，以及一小部分特别致命的“癌症干细胞”（CSCs），它们对治疗有抵抗力，可能导致癌症复发。因此，为了实现长期的缓解和潜在的治愈，不仅需要新的策略来靶向和杀死大多数成熟癌细胞，还需要新的策略来杀死csc。为此，Siamab Therapeutics, Inc.设计了一种独特的方法，使用单一治疗性单克隆抗体（mAb）靶向肿瘤的成熟和CSC成分

Within a tumor there are two main cell types: mature cancer cells comprising the majority of a tumor and a small population of especially lethal “cancer stem cell (CSCs) resistant to treatment that can cause cancer relapse. Thus, novel strategies are needed to target and kill not only the majority of mature cancer cells but also the CSCs in order to achieve long-­‐term remissions and potential cures. Toward this end, Siamab Therapeutics, Inc. has devised a unique approach to target both mature and CSC components of a tumor using a single therapeutic monoclonal antibody (mAb) that targets a cancer-­‐associated cell-­‐surface carbohydrate antigen.